Posted by Michael Wonder on 23 Nov 2021
Seqirus announces U.S. FDA approval for multi-dose vial presentation of first ever adjuvanted, cell based pandemic influenza vaccine
23 November 2021 - The FDA has granted approval of multi-dose vial presentation for Audenz to help protect individuals six months of age and older against influenza A(H5N1) in the event of a pandemic.
Seqirus today announced that the U.S. FDA has granted supplemental approval of a multi-dose vial presentation of Audenz (influenza A(H5N1) monovalent vaccine, adjuvanted), the first-ever adjuvanted, cell based influenza vaccine designed to help protect individuals six months of age and older against influenza A(H5N1) in the event of a pandemic.
